Qulipta FDA Approval History
Last updated by Judith Stewart, BPharm on Oct 5, 2021.
Qulipta (atogepant) is an oral, calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of episodic migraine in adults.
- Qulipta works by blocking CGRP receptors to prevent migraine. CGRP and CGRP receptors are expressed in regions of the nervous system associated with migraine pathophysiology.
- Atogepant belongs to the gepant class of CGRP receptor antagonists which are small molecules intended for oral administration. The larger molecule monoclonal antibody CGRP antagonists need to be administered via injection.
- Qulipta tablets are taken orally once daily with or without food.
- Common adverse reactions include nausea, constipation, and fatigue.
Development timeline for Qulipta
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.